The study for the effects of Interluekin-11 on cardiac remodeling following recanalization therapy against myocardial infarction.
Project/Area Number |
22590160
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Medical pharmacy
|
Research Institution | Hyogo University of Health Sciences |
Principal Investigator |
MAEDA Makiko 兵庫医療大学, 薬学部, 講師 (70461168)
|
Co-Investigator(Kenkyū-buntansha) |
AZUMA Junichi 兵庫医療大学, 薬学部, 教授 (30144463)
FUJIO Yasushi 大阪大学, 大学院・薬学研究科, 教授 (20359839)
|
Project Period (FY) |
2010 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Keywords | 心筋細胞 / サイトカイン / 心筋梗塞 / シグナル / 虚血再灌流 / 臨床研究 / 心不全 / インターロイキン-11 / 虚血・再灌流 / STAT3 / インターロイキン-11(IL-11) / 虚血・再灌流傷害 / Signal transducere and activator of transcription 3(STAT3) / 遺伝子改変動物モデル |
Research Abstract |
Activation of cardiac STAT3 by IL-6 cytokine family contributes to cardioprotection. Previously, we demonstrated that IL-11, an IL-6 cytokine family, has the therapeutic potential to prevent adverse cardiac remodeling after myocardial infarction. In this study we investigated the postconditioning effects of Interluekin-11 (IL-11) on ischemia/reperfusion (I/R) injury to address the possibility that IL-11 treatment improves clinical outcome of recanalization therapy against acute myocardial infarction. In addition, we clinically determined that the serum concentration of IL-11 before and after percutaneous coronary intervention against myocardial infarction. As a result, IL-11 administration exhibits the postconditioning effects through cardiac STAT3 activation, and the serum concentration of IL-11 was undetectable before and after recanalization therapy against myocardial infarction. The results of this study will propose the possibility of IL-11 as a novel cytokine therapy to prvent heart failure.
|
Report
(4 results)
Research Products
(23 results)
-
[Journal Article] Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart2012
Author(s)
Obana M, Miyamoto K, Murasawa S, Iwakura T, Hayama A, Yamashita T,Shiragaki M, Kumagai S, Miyawaki A, Takewaki K, Matsumiya G, Maeda M, Yoshiyama M, Nakayama H, Fujio Y.
-
Journal Title
Am J Physiol Heart Circ. Physiol
Volume: 303(5)
Issue: 5
Pages: 569-77
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] IL-6-mediated Th17 differentiation through RORγt is essential for the initiation of experimental autoimmune myocarditis.2011
Author(s)
Yamashita T, Iwakura T, Matsui K, Kawaguchi H, Obana M, Hayama A,Maeda M, Izumi Y, Komuro I, Ohsugi Y, Fujimoto M, Naka T, Kishimoto T, Nakayama H, Fujio Y.
-
Journal Title
Cardiovasc Res.
Volume: 91(4)
Pages: 640-8
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Pim-1 kinase is required for endothelial differentiation of cardiac stem cells via STAT3 signaling pathway2010
Author(s)
Tomohiko Iwakura, Tomomi Mohri, Tomomi Yamashita, Masanori Obana, Akiko Hayama, Makiko Maeda, Hiroyuki Nakayama, Issei Komuro, Junichi Azuma, Yasushi Fujio
Organizer
The American Heart Association Scientific Sessions
Place of Presentation
Chicago, Illinois, USA
Year and Date
2010-11-07
Related Report
-
-
-
-